FY25 consensus $119/5M. Cites delayed Etorel rollout and government procurement-related uncertainty.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics reports Q3 EPS 3c, consensus (2c)
- Buy Rating for Gyre Therapeutics Driven by Phase 3 Trial Progress and Strategic Asset Valuation
- Gyre Therapeutics completes enrollment in Phase 3 trial of Pirfenidone capsules
- Gyre Therapeutics initiated with a Buy at Jefferies
- Gyre Therapeutics Announces Positive Phase 3 Results